AUTHORS
Patrick Harrington, MD, Filippo Branzanti, MSc2, Lucía Pérez-Lamas, MD3, Bethan Psaila, Md PhD4, Alberto Alvarez-Larran, MD5, Giuseppe Palumbo6, Alexandros Rampotas, MD, PhD, MRCP7, Juan Carlos Hernandez Boluda, MD, PhD8, Monia Marchetti, MD, PhD9, Tim Somervaille10, Maria Isabel Mata Vazquez11, Elena Maria Elli12, Joanne Ewing13, Sara Garrido Paniagua14, Ilaria Gianesello15, Andrew McGregor, MD16, Regina Garcia Delgado, MD17, Alessandro Lucchesi, MD, PhD18, Ali Mahdi, MD19, Alberto Marin Sanchez20, Novella Pugliese, MD, PhD21, Graeme M Greenfield, MD22, Elvira Mora Mora Casterá, MD23, Sara Galimberti, MD24, Sebastian Francis25, Jasson Villarreal Hernandez, MD26, Erika Morsia, MD27, Peter Dyer28, Natalia De Las Heras Rodriguez, MD, PhD29, Mamta Garg, MD, FRCP, FRCPath30, Paula Gomez Fernandez, MD31, Steve Knapper32, Teresa Cobo33, Andrew Innes, MD PhD34, Adrian Segura Diaz, PhD35, Andrew Robinson36, Santiago Osorio Prendes37, Kirsty Crozier38, Kyaw Htin Thaw39, Francesca Palandri, MD, PhD40, Valentín García Gutiérrez I, MD41
AFFILIATIONS
2 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
3 Hospital Universitario Puerta de Hierro. Universidad de Alcalá., Madrid, Spain
4 University of Oxford, Oxford, United Kingdom
5 Hospital Clínic de Barcelona, Barcelona, Spain
6 Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia”, University of Catania, Catania, Italy
7 UCL, London, United Kingdom
8 Hospital Clinico Universitario de Valencia, Valencia, Spain
9 Hematology and Transplant Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
10 Cancer Research UK Manchester Institute & The Christie NHS Foundation Trust, Manchester, United Kingdom
11 Hospital Universitario Costa del Sol, Málaga, Spain
12 Hematology and Transplant Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
13 University Hospital Birmingham, Birmingham, United Kingdom
14 Hospital Universitari Vall d’Hebron, Barcelona, Spain
15 Hematology and Clinical Immunology, Department of Medicine, University of Padua, Padova, Italy
16 Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom
17 Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
18 Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori', Meldola, Italy
19 Aneurin Bevan University Health Board, Newport, United Kingdom
20 Hospital General Universitario de Albacete, Albacete, Spain
21 Hematology Section, Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy
22 Queen's University Belfast, Belfast, United Kingdom
23 Hospital Universitario y Politécnico de La Fe, Valencia, Spain
24 Dipartimento di Medicina Clinica e Sperimentale, UO Ematologia, Università di Pisa and AOUP, Pisa, Italy
25 Sheffield Teaching Hospital NHS Trust, Sheffield, United Kingdom
26 Hospital Duran i Reynals — ICO L'Hospitalet, Barcelona, Spain
27 Hematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy
28 University Hospitals of North Midlands, Stoke, United Kingdom
29 Hospital Universitario de León, León, Spain
30 Leicester Royal Infirmary, Leicester, United Kingdom
31 Hospital Universitario Son Espases, Palma de Mallorca, Spain
32 Cardiff University School of Medicine, Cardiff, United Kingdom
33 Hospital Universitario del Sureste, Madrid, Spain
34 Imperial College London, London, United Kingdom
35 Hospital Universitario Doctor Negrín. Istituto de Investigación Sanitaria de Canarias (IISC)., Las Palmas de Gran Canaria, Spain
36 East Suffolk and North Essex NHS Foundation Trust, Colchester, United Kingdom
37 Hospital Universitario Gregorio Marañón, Madrid, Spain
38 University of Oxford, Oxford, United Kingdom
39 Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
41 Hospital Universitario Ramón y Cajal — IRYCIS; Universidad de Alcalá, Madrid, Spain
ABSTRACT
Background: Momelotinib is a recently approved JAK inhibitor (JAKi) for patients with myelofibrosis (MF) requiring treatment for disease-related symptoms and anemia. Although clinical trials have demonstrated significant improvements in symptoms and anemia, large international real-world studies with extended follow-up remain limited.
Methods: We conducted a multicenter, international, retrospective real-world study of MF patients treated with momelotinib using data from three national registries (Spain, UK and Italy) between January 2023 and March 2026. Individual patient-level data from the Spanish and UK registries were pooled and analyzed jointly, whereas the Italian registry contributed aggregated data because of local data-sharing restrictions. These data were included in descriptive analyses when comparable variables were available. Anemia response was assessed according to the 2024 ELN-IWG criteria and spleen response according to the 2013 IWG-MRT/ELN criteria, both at 6 months.
Results: A total of 646 patients treated with momelotinib from 129 European centers were included. Overall, 513/646 (79.4%) had received prior JAKi therapy, whereas 20.6% were JAKi-naïve. Median follow-up from momelotinib initiation was 10.94 months (range 0.2–58 months).
Overall, 59.4% were male, with a mean age of 72 years (SD, 9.01). Driver mutation distribution was as follows: JAK2 (62%), CALR (22%), MPL (10%), and triple-negative disease (5%). Additional high-risk mutations included ASXL1 (25.8%), SRSF2 (8.6%), EZH2 (6.5%), IDH1/2 (3.8%), and U2AF1 (8.4%). According to the DIPSS, 8.4% were classified as intermediate-1 risk, 52.5% as intermediate-2 risk, and 30.1% as high risk.
Mean baseline hemoglobin was 8.7 g/dL (SD, 1.45). Mean platelet count was 208×10⁹/L (SD, 218; range, 3–2570), with 81 patients (12.5%) having a baseline platelet count below 50x10⁹/L. Overall, 49% were transfusion-dependent (≥1 red blood cell unit/month). At baseline, 73% had splenomegaly, with a mean spleen size of 7.5 cm below the left costal margin (SD, 5.95).
Among the 421 evaluable patients for anemia response, 273 (64.8%) achieved an anemia response, including 41.3% with a major response and 23.5% with a minor response. Among transfusion-dependent patients 67.6% achieved a response (35.3% major, 32.3% minor) and in transfusion-independent group 61.8% (48.9% major, 12.9% minor). Stratified by prior JAKi exposure, anemia response was achieved in 67% of JAK inhibitor-exposed patients (43.6% major, 23.4% minor) compared with 58.6% of JAK inhibitor-naïve patients (34.3% major, 24.3% minor). Among the 268 evaluable patients with a baseline spleen size >5 cm below the left costal margin, 17.5% achieved a spleen response by 2013 IWG-MRT criteria.
Regarding safety, hematologic adverse events (AEs) included thrombocytopenia in 8.7% of patients (6% grade (g) 3–4), whereas thrombocytosis was reported in 8 patients (1.2%). Anemia occurred in 21 patients (3.3%), including g3–4 events in 1.7%. Neutropenia was uncommon (0.5%). The most common non-hematologic AEs were gastrointestinal toxicity (13%; 1.2% g3, most commonly diarrhea [6.7%], followed by nausea [4.6%]), infections (8.4%), peripheral neuropathy (5.4%; all g1–2), hepatic toxicity (3.1%; 1.4% g3–4), renal toxicity (2.3%; 0.9% g3), asthenia (1.7%; 0.5% g3–4), cognitive impairment (1.4%; all g1–2), skin disorders (1.2%), and hypotension (0.8%). Only two patients developed non-melanoma skin cancer as a treatment-emergent AE. Dose modifications due to AEs were required in 18.3% of patients, and temporary dose reductions in 11.9%.
At last follow-up, 35.5% had discontinued momelotinib. Reasons for discontinuation included toxicity (22.7%), death (22.3%), lack of efficacy (13%), allo-HSCT (10%), transformation to blast phase (7.9%), disease progression (6.6%), combined toxicity and lack of efficacy (15.3%), other reasons (0.9%), and unknown causes (1.3%).
Conclusions: This study represents the largest real-world analysis of momelotinib reported to date, with a median follow-up approaching one year. In this large European cohort, momelotinib demonstrated sustained clinical effectiveness in routine practice, including in a predominantly JAK inhibitor-exposed population, confirming the reproducibility of clinical trial outcomes in the real-world setting. Despite the heavily pretreated nature of the cohort, spleen response rates were consistent with those reported in previous studies of JAK inhibitor-exposed patients.
DISCLOSURES
Francesca Palandri, MD, PhD: GlaxoSmithKline - Honoraria; Novartis - Honoraria; Amgen - Honoraria; Grifols - Honoraria; Incyte - Honoraria; Bristol Myers Squibb - Honoraria; AOP Health - Honoraria; Takeda - Honoraria; Sobi - Honoraria; Sanofi - Honoraria; GlaxoSmithKline - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Grifols - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); AOP Health - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony)